

## Riluzole Zentiva

Procedural steps taken and scientific information after the authorisation\*

\*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification  1 issued on	Product Information affected <sup>3</sup>	Summary
Article 61(3) /	- Notification acc. Article 61(3) -	15/05/2025	PL	

<sup>&</sup>lt;sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.



<sup>&</sup>lt;sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>&</sup>lt;sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

EMA/N/0000269434			
	Update of the package leaflet with revised		
	contact details of local representatives and		
	deletion of 'United Kingdom (Northern		
	Ireland)' from the list of local		
	representatives in line with the QRD		
	template v10.4. Furthermore, the MAH took		
	the opportunity to introduce additional minor		
	updates to align with the latest QRD		
	template v10.4.		